179625-70-8Relevant articles and documents
Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times
Mollica, Luca,Theret, Isabelle,Antoine, Mathias,Perron-Sierra, Fran?oise,Charton, Yves,Fourquez, Jean-Marie,Wierzbicki, Michel,Boutin, Jean A.,Ferry, Gilles,Decherchi, Sergio,Bottegoni, Giovanni,Ducrot, Pierre,Cavalli, Andrea
supporting information, p. 7167 - 7176 (2016/08/24)
Ligand-target residence time is emerging as a key drug discovery parameter because it can reliably predict drug efficacy in vivo. Experimental approaches to binding and unbinding kinetics are nowadays available, but we still lack reliable computational to
AMINOPHENYLPROPANOIC ACID DERIVATIVE
-
Page/Page column 48-49, (2010/11/24)
A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man
Abe, Yoshito,Kayakiri, Hiroshi,Satoh, Shigeki,Inoue, Takayuki,Sawada, Yuki,Inamura, Noriaki,Asano, Masayuki,Hatori, Chie,Sawai, Hiroe,Oku, Teruo,Tanaka, Hirokazu
, p. 4053 - 4061 (2007/10/03)
Recently we reported the identification of a series of 8-[[3-(N- acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]-3-halo-2-methytimidazo[1,2- α]pyridines as the first orally active non-peptide bradykinin (BK)B2 receptor antagonists (1-3). Thes
